chrisvoncsefalvay/vaers-outcomes huggingface dataset:
mentally out of it for 5 days; did not recognize anyone; This spontaneous case was reported by a pharmacist and describes the occurrence of MENTAL DISORDER (mentally out of it for 5 days) and MEMORY IMPAIRMENT (did not recognize anyone) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Psychiatric disorder NOS (has been stabilized for 40 years). Concomitant products included CLOZAPINE, VALPROATE SEMISODIUM (DIVALPROEX), ZIPRASIDONE HYDROCHLORIDE (GEODON [ZIPRASIDONE HYDROCHLORIDE]), LAMOTRIGINE (LAMICTAL), BENZATROPINE MESILATE (COGENTIN), L-METHYLFOLATE, LEVOTHYROXINE, FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), CROMOGLICATE SODIUM (NASALCROM), ALBUTEROL [SALBUTAMOL], CALCIUM, MULTIVITAMIN [VITAMINS NOS] and FISH OIL for an unknown indication.    In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MENTAL DISORDER (mentally out of it for 5 days) and MEMORY IMPAIRMENT (did not recognize anyone). At the time of the report, MENTAL DISORDER (mentally out of it for 5 days) and MEMORY IMPAIRMENT (did not recognize anyone) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient visited an orthopedic surgeon regarding an unspecified procedure and during the consultation she got up from the chair and started walking around like she did not recognize anyone. After 5 days she was back to normal like a switch was turned.   No treatment details were reported.
Shortness of breath; chest pain upon exercise; Elevated heart rate; This is a spontaneous report from a contactable consumer (patient). A 27-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 at the age of 27-year-old, via an unspecified route of administration, administered in left arm on an unspecified date (Lot Number: En6199) as dose 1, single for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient was not pregnant at the time of vaccination. The patient experienced shortness of breath, chest pain upon exercise, and elevated heart rate on an unspecified date. The patient did not receive any treatment for the events. The outcome of the events was unknown.  No follow-up attempts are possible. No further information is expected.
Pt received 1st GARDASIL 11-7-07, 2nd GARDASIL 1-29-08, DX with Pancreatitis 5-7-08. x\x of pancreatitis 4-24-08. Recovered 5-21-08 DX with cholecystitis on 5-23-08. 5/7/08 also dx with mono.  08/26/2008 MR received for DOS 5/7-8/2008 with D/C DX:  Acute Pancreatitis.  Nausea with vomiting.  Abdominal pain. Mono. Mesenteric lymphadenopathy. Pt presented to ER with 2 wk hx of nausea with vomiting, fatigue and sore throat. Initially dx with H pylori, now with worsening LUQ pain, N&V.  Increased lipase and amylase on labs.  Tx with IV hydration and abx. Improved and d/c next day.
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 26-APR-2016 the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB 50 U/1 ml (lot # L039660, expiration date: 04-Feb-2018; dose, frequency and route unspecified). No adverse effects were reported. The storage criteria was refrigerator (R). Celsius conversion of the lowest recorded temperature was 1.111111111 (Fahrenheit degree/Celsius). The total cumulative excursion time was 80 hours with the lowest recorded temperature 34 (Fahrenheit degree/Celsius) and the type of excursion (R/F) was R. This is one of several reports received from the same source. Additional information has been requested.
Client received Prevnar 20 vaccination on 6/8/22, data base was not updated, and client was given a second dose of Prevnar 20 on 11/1/22.
She was here to get her second moderna shot and was given the pfizer by mistake.  She is fine. I have checked on her twice and I spoke with Moderna and they said she would not need to be revaccinated at this time.  The pfizer lot  was ff8839 exp 12/21
11/02/2021, pt was having a conversation with the spouse and pt felt that his face was twisted and felt dizzy.  Pt proceed to Er and was diagnosed with Bell's Palsy,  Pt was treated with accyclovir  I q8h x 7days and predinsone as directed #30 and artificial eye gtt 1.4% as directed.  Pt was followed up with the Primary care Physician Nov 4th, 2021 and pt has an appointment with the ophth 11/10/2021 and ENT referral, pending the appointment.
January 8th and 9th I experienced shooting pain at the injection site of the vaccine. It felt like the neuropathy pain that I have with my feet. I held the arm tight and applied an ice pack and slept with the ice pack as it started about 7pm. The next evening the shooting pain started again. I used an ice pack and took Zyrtec.  The only other issue I had was itching at the site which started on the 6th and ithed for about 3 days. I notified Dr via pt portal tonight.
8 days after the vaccine, my arm was red, hot, and tender to touch at the injection site.  Immediately after the injection, I developed a red 2in circle at the site,  this went away after 2 days.  It returned 8 days later as stated above.  I was started in a 7 day course of antibiotics by my PCP.   I had a 2 in circular red spot that was hot, tender, and itchy at times.  My arm was red as far down as my elbow.
Pt vaccinated w/1st dose of vax w/o adverse experience; Vaccinated w/2nd dose JUL89 & 2 hrs later developed h/a, dizziness, ear pain, sinus infect & sx of URI;
I developed hives, itching from head to toe and throat felt restricted. I went to 2 ER visits was given IV and steroids. The symptoms lasted for 6 weeks.
5-4-07 MMR given at 10:00AM, 45 minutes later at 10:45AM came back to office c/o rash, itchiness, scratchy throat to took pt to ER - given Solu Medrol IV, Benadryl IV - within hours started to increase pruritus, some burning, SOB - addition Solu med IV, oral prednisol. pepcid, Benadryl - admitted to hospital for overnight observation.  05/24/2007 MR received for an o/n admit (5/4-5/2007) for c/o rash and scratchy throat.  Symptoms improved somewhat with tx in the ER but then worsened to include pruritis, burning, and SOB. Pt. improved o/n and was D/C. Final Discharge DX: Allergic reaction.
pt recv vax & approx 15mon p/vax pt devel possible cases of varicella;
the patient had his second dose over 3 months later; This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the patient had his second dose over 3 months later) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the patient had his second dose over 3 months later). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (the patient had his second dose over 3 months later) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
High fever 101; chills; fatigue; body joint pain; This spontaneous case was reported by a physical therapist and describes the occurrence of PYREXIA (High fever 101), CHILLS (chills), FATIGUE (fatigue) and ARTHRALGIA (body joint pain) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Jan-2021, the patient experienced PYREXIA (High fever 101), CHILLS (chills), FATIGUE (fatigue) and ARTHRALGIA (body joint pain). At the time of the report, PYREXIA (High fever 101), CHILLS (chills), FATIGUE (fatigue) and ARTHRALGIA (body joint pain) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 17-Jan-2021, Body temperature: 101.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information provided.
Breakthrough case admission after three vaccines Moderna 2/28/21 Lot# 015M20A;  Moderna 3/25/21 Lot# 030A21A;  Moderna 10/27/21 Lot# 024C21A
bulluous pemphigoid; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 11Nov2022 at 11:00 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 47 years, in left arm for covid-19 immunisation; influenza vaccine inact sag 3v (FLUCELVAX), on 11Nov2022 as unk, single (Batch/Lot number: unknown) for immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose Number: 3, Batch/Lot No: FH8028, Location of injection: Arm Left, Vaccine Administration Time: 09:00 AM), administration date: 18Nov2021, when the patient was 46-year-old, for Covid-19 immunization, reaction(s): "bulluous pemphigoid", "itchy blisters on my skin", "itchy blisters on my skin"; Covid-19 vaccine (Dose Number: 2, manufacturer unknown), for Covid-19 immunization; Covid-19 vaccine (Dose Number: 1, manufacturer unknown), for Covid-19 immunization. The following information was reported: PEMPHIGOID (medically significant) with onset 21Nov2022, outcome "not recovered", described as "bulluous pemphigoid". The event "bulluous pemphigoid" required physician office visit. Therapeutic measures were taken as a result of pemphigoid. Clinical course: The patient was given oral and topical steroid and it improved. This time it is lasting longer. The blisters begin as itchy and if she scratched them they would pop and turn into a scab to heal. She has never had any of these symptoms before receiving the covid vaccine.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300120267 same patient/vaccine, different dose/events;US-PFIZER INC-202300120268 same patient/vaccine/event, different dose;
This spontaneous report as received from a medical assistant refers to approximately 14 year old female patient. Medical history was not reported. Drug reactions/allergies were none. Concurrent condition included cognitive disorder. On 14-NOV-2011, the patient was vaccinated with a first dose of GARDASIL. Concomitant therapy included IMPLANON. On 11-MAR-2013, the patient was vaccinated with a second dose and on 05-NOV-2013, with the third dose of GARDASIL (inappropriate schedule of drug administration). Approximately on 19-SEP-2015 (a couple days ago), the patient experienced vaginal itching and was then diagnosed with genital warts (anogenital warts). No treatment was provided. On 21-SEP-2015, the following test were performed RPR (Rapid Plasma Reagin) to test for syphilis, hepatitis panel, HIV test, urine test to check for gonorrhea and chlamydia. Results were not provided. Patient sought medical attention (had come to the office on 21-SEP-2015 because of the event). The outcome of anogenital warts was not recovered/not resolved. The causality of anogenital warts was not provided. Additional information has been requested.
Severe cough /Cough getting worse; Nights of sweat; like a bronchitis cough; swelling; redness on skin; fever / high temperature; tiredness; headache; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Severe cough /Cough getting worse), NIGHT SWEATS (Nights of sweat), BRONCHITIS (like a bronchitis cough), SWELLING (swelling) and ERYTHEMA (redness on skin) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 24-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COUGH (Severe cough /Cough getting worse), NIGHT SWEATS (Nights of sweat), BRONCHITIS (like a bronchitis cough), SWELLING (swelling), ERYTHEMA (redness on skin), PYREXIA (fever / high temperature), FATIGUE (tiredness) and HEADACHE (headache). At the time of the report, COUGH (Severe cough /Cough getting worse), NIGHT SWEATS (Nights of sweat), BRONCHITIS (like a bronchitis cough), SWELLING (swelling), ERYTHEMA (redness on skin), PYREXIA (fever / high temperature), FATIGUE (tiredness) and HEADACHE (headache) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate: 105 (High) high heart rate of 105 when laying down.         No concomitant medications were reported.  No treatment medications were provided by the reporter.  On day 4 patient had no sweat at night   Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: follow-up was received and contains no significant information.
Shortly after vaccine administration pt alerted monitor nurse she felt "dizzy" then syncopal. pt was transferred to observation room via wheelchair where she was then semi responsive. vitals at  on immediate arrival to observation room; 127/103, pulse 68 resp 16 at 100%room air. pt then mentioned she was diabetic, at which time she was provided juice. 1300 pt was A&O times 3, skin dry and warm and was "feeling better". pt was wheeled back out to main waiting room upon her request. at 1330 pt stated she was feeling week again. pt transported to ER for further evaluation of blood glucose. pt evaluated in ED and d/c shortly after. vss wdl, ecg wdl, bgl wdl.
This spontaneous report as received from a 55 year old female consumer with allergy to vancomycin, to LEVAQUIN, to AXID, ESTRING, to sulfa, to latex and with alpha-1 antitrypsin abnormal level. The patient's medical history included breast cancer, shingles and ventricular tachycardia (dates unknown). On 18-NOV-2014 the patient was subcutaneously vaccinated with one injection of ZOSTAVAX (exact dose, lot# and expiration date were not reported). Concomitant therapies included KLOR-CON, triamterene, hydrochlorothiazide (manufacturer unknown) reported as HCTZ, digoxin and nadolol. On 18-NOV-2014 the patient experienced a slight reaction to ZOSTAVAX as soon as it was administered (redness and mild pain). On the following day (on 19-NOV-2014), the patient experienced two red welts, pain and itching at the injection site of where she was injected with the ZOSTAVAX vaccine. The redness spread (on the following day as well, on 19-NOV-2014) from the injection site to her elbow. The areas (two separate areas) were "warm to the touch". One area was "bright red" in color in comparison to a darker red in the other areas of the outbreak. On an unknown date, in November 2014 the patient was diagnosed with cellulitis due to an allergic reaction and possibly a staph infection and or possibly MRSA (methicillin-resistant Staphylococcus aureus). The patient sought medical attention in emergency room and was admitted to hospital on an unknown date, in November 2014 and was treated with vancomycin, BENADRYL intravenous (i.v.) and with clindamycin. The patient had blood culture test and regular laboratory work performed with no results provided (date unspecified). The patient was told to follow-up with her cardiologist. At the time of the report, the outcome of the events was not recovered. The relatedness between the events and ZOSTAVAX was not reported. Upon internal review the event of "allergic reaction" was considered to be medically significant as required treatment with BENADRYL by the intravenous route. Additional information has been requested.
Daughter brought in a picture of a red area with a white spot in the center. Site was itchy and red. Told daughter to take her mother to a clinic and have it looked at. Area looked irritated from possible scratching.
1st dose- Pfizer- 24Jan2021,2nd dose- Moderna- 08Nov2021; This spontaneous case was reported by a consumer and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (1st dose- Pfizer- 24Jan2021,2nd dose- Moderna- 08Nov2021) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 076C21A) for COVID-19 vaccination.     Previously administered products included for COVID-19 vaccination: Pfizer (transported to hospital) on 24-Jan-2021. Past adverse reactions to the above products included Adverse reaction with Pfizer.    On 08-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Nov-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (1st dose- Pfizer- 24Jan2021,2nd dose- Moderna- 08Nov2021). On 08-Nov-2021, INTERCHANGE OF VACCINE PRODUCTS (1st dose- Pfizer- 24Jan2021,2nd dose- Moderna- 08Nov2021) had resolved.            No concomitant medication was provided. No treatment information was provided.  It was reported that, 1st dose Pfizer Lot Number EL3247.
Patient is a pleasant 27 year old female who presents today with complaints of left lateral shoulder pain with gradual onset on 10/11/18, the day after she received the yearly influenza vaccine. She describes the pain as a sharp pain. For one week after the immunization, she states her symptoms gradually worsened, with pain noted only with certain arm/shoulder movements (none at rest) then reached a plateau, not worsening but not improving. Is being seen today because her pain in her shoulder worsened again this past weekend while she was playing ball with her son. At its worst, she rates it as an 8-9/10; this is only with certain movements. At rest, it continues to be a 0-1/10. She is a weight lifter and has been avoiding lifting weights due to her current condition. She denies any particular activities that she may have done recently to worsen the pain. Her pain has been present for 3 weeks now.
Redness, warmth, and induration 15cm x 15cm on right thigh.
Blue/black blood clot on middle finger right hand; Burning in middle finger on right hand; Itchiness on middle finger on right hand; Pain in middle finger on right hand; A spontaneous report was received from a Consumer concerning a 55-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events burning in middle finger on right hand/burning sensation, itchiness on middle finger on right hand/pruritus, pain in middle finger on right hand/pain in extremity, blue black blood clot on middle finger right hand/thrombosis.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 2 Jan 2021, prior to the onset of the events the patient received their first of two planned doses of mRNA-1273 (lot batch: 037K20A) intramuscularly for prophylaxis of COVID-19 infection.  On 20 JAN 2021 1.00 pm, after taking mRNA-1273, the patient felt weird sensation in right hand middle finger. She felt burning, itchiness, pain and had a dark blue/black blood clot on inside of finger. 2 hours later it started to fade down (purple in color). In the evening it was considerably lighter. On 21 Jan 2021 there was a light imprint of the blood clot. Blood clot went away later that day. Patient did not received treatment.  Action taken with mRNA-1273 in response to the events was not reported.  On 20 Jan 2021 the outcome of events burning in middle finger, itchiness on middle finger on right hand, pain in middle finger on right hand was resolving. On 21 Jan 2021 the outcome of event blue black blood clot on middle finger right hand was resolved.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.  Further information has been requested.
Fatigue, upset stomach, a slow moving wave of pain that eventually became full body by the following morning.  Followed by more stomach pain, abdominal cramping, rage, and confusion into the following days. Side effects lasted a week.
Information  has been received from a physician concerning a pediatric patient who on an unspecified date was vaccinated with a dose of VARIVAX (Merck). Subsequently the patient experienced an unspecified allergic reaction after the vaccination. The patient sought unspecified medical attention. At the time of the report, the patient status was unknown. Additional information has been requested.
having seasonal allergies; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 09Mar2021 as single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient wanted to know if he can take over the counter because he started having seasonal allergies, which was non-serious on unspecified date in Mar2021. The patient received the first vaccine dose on 09Mar2021. Outcome of the event was unknown.  Follow-up (05Apr2021): This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts have been completed and no further information is expected.
Arm soreness; This is a spontaneous report from a Pfizer sponsored program. A contactable consumer reported (patient) that a 49-years-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/lot number: un EWO185) via an unspecified route of administration on 25May2021 14:48 (age at vaccination 49years old) as single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The patient experienced arm soreness on an unspecified date. The clinical outcome of the event was unknown.  Information on Lot/Batch number was available. Additional information has been requested.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021716077 similar report from same reporter
On March 24,2009 received injection of Zostavax and by April 8th, experienced extreame anxiety, inability to sleep, and by May 7th was hospitalized for anxiety, loss of memory and by May 16th has slipped into severe depression and again hospitlized and  treated with 12 ECT (Electro Convulsive Therapy)to encourage brain activity.  Brain had slowed down drastically -patient very non-communicative and very agitated/depressed. Currently taking 300 mg. Vistaril, 20 mg. Lexapro, 50 mg. Trazodone, and 30 mg. daily to treat depression and axiety.  Patient recovering at home. 7/22/10 Continued Anxiety/Nervous disoder.
My symptoms were I was dizzy; my mouth and tongue swollen and burning;  my scalp very itchy the same day as vaccine.   Called my primary care Doctor.   She advised that I take my second vaccine and get observered for one hour.
I had Covid in December 2020. I also experienced after my vaccine, SOB and was not able to full breaths. I also experienced body aches, fatigue, soreness to my left arm.  On 01-15-2021 I went to urgent care where an x-ray of the chest was performed.  I do not have any of my symptoms today.  I do not have lot# to provide.